KAG-308 / Kaken Pharma - LARVOL DELTA

Activation of prostaglandin E receptor 4 attenuates pulmonary vascular remodeling and pulmonary hypertension in monocrotaline-exposed rats via non-inflammatory pathway (AHA 2024) - "KAG-308 ameliorated pulmonary vascular remodeling and PH in MCT-exposed rat, whereas it didn't show anti-inflammatory effect but anti-proliferative effect in human PASMCs. Although EP4 agonist KAG-308 could be a potential therapeutic agent for the treatment of PAH, the mechanism of anti-proliferation remains to be elucidated."

Preclinical • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Osteoarthritis • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Ulcerative Colitis • IL1B • IL6 • PTGER4 • TNFA

Activation of Prostaglandin E Receptor 4 Ameliorates Perivascular Inflammation and Pulmonary Hypertension in Rats (AHA 2023) - "EP4 agonist ameliorated inflammation, vascular remodeling and PH in MCT-exposed rat. The EP4 agonist KAG-308 is a potential therapeutic agent for the treatment of PAH."

Preclinical • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hypertension • Inflammation • Inflammatory Bowel Disease • Osteoarthritis • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Ulcerative Colitis • IL6 • PTGER4

Oral administration of EP4-selective agonist KAG-308 suppresses mouse knee osteoarthritis development through reduction of chondrocyte hypertrophy and TNF secretion. (PubMed, Sci Rep) - "Thus, we conclude that oral administration of KAG-308 suppresses OA development through suppression of chondrocyte hypertrophy and synovitis. KAG-308 may be a potent candidate for OA drug development."

Journal • Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology